BioSpace News Archive

Cue Health Inc. (“Cue Health”) (Nasdaq: HLTH), a health technology company, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a public offering price of $16.00 per share.

Femasys Inc. will participate in a presentation at The MedTech Conference.

SCYNEXIS, Inc. today announced one oral and two poster presentations of interim data from its Phase 3 FURI study, evaluating oral ibrexafungerp for the treatment of patients with refractory mucocutaneous and invasive fungal infections, will be presented at IDWeek 2021

Pear Therapeutics, Inc. today updated the number of entities providing coverage for its three commercial products, reSET®, reSET-O®, and Somryst®.

Scopus BioPharma Inc. today announced it will be presenting at the Benzinga Healthcare Small Cap Conference on Wednesday, September 29, 2021.

Petros Pharmaceuticals, Inc. , announces today that President and Chief Commercial Officer Fady Boctor will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 - 30, 2021 .

Horizon Therapeutics plc Announces Data Showing UPLIZNA ® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)

BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance for a patent application for its metabolic ThermoStem® program.

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders and the market with an update to our market announcements of 8 June 2021 and 7 July 2021.

Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines